Interview With Sacha Hebbert

What’s up Psychedelic Investors? In today’s episode entitled :Important Correction for MindMed Trials (Plus Changes In MMED/MMEDF’S Timelines), we discuss a correction I have to make to my MindMed (MMED / MMEDF) coverage regarding their clinical trials treating addiction with 18MC, and ADHD with LSD microdoses. The start dates for these phase 2a trials have been postponed until the third quarter of 2021, and have not yet started.

MindMed is the leader in psychedelic medicines, and is my top Psychedelic Stock. Is MindMed a buy? Is MindMed a good Investment? Watch our channel to find out!

Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!

Follow us on social media!
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
Music: www.bensound.com

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

#MindMed #MMED #MMEDF

Hey guys! I promised ya’ll that I will keep you updated on Compass Pathways (NASDAQ: CMPS) earnings call. There has been some pretty interesting developments on the company that I thought I should Bring to your attention. Compass Pathways is one of the psychedelic companies that is the furthest advanced in their clinical trials (Phase IIB to treat TRD). However, I wasn’t aware that they are doing a LOT more. This is quite interesting because in my opinion, CMPS is not a one trick pony anymore and it might as well be in direct competition with my favorite company in this sector (MindMed).

In this video, we’ll cover:
1. Compass Pathways’ Financials
2. Their IP
3. Therapists Training
4. Future Projects
5. Digital Technology

I hope that this is not going to enrage the MindMed fan boys out there. I just thought that it might be interesting for some of you psychedelic investors.
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!

Follow us on social media!
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
Music: www.bensound.com

https://mindmed.co/wp-content/uploads/2020/11/investor-deck.pdf
https://www.businesswire.com/news/home/20190905005528/en/Usona-Institute-Clinical-Trial-Psilocybin-Major-Depressive

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

#CompassPathways #CMPS #MindMed

Hey psychedelic investors, this week we have Big Updates on MindMed, Compass, NUMI TRYP, TRUFF, ATAI, SHRM and LOBE Sciences and some amazing Ayahuasca study results which are detrimental to DMT research and this molecule potential effects on depression and anxiety.

Timestamps:
0:00 – Intro
0:52- Effects of DMT, taken using the ayahuasca drink, on depression and anxiety
5:26 – MindMed ( MMED / MNMD / MMQ ) stared trading on NASDAQ
6:01 – MindMed finishes phase2a trials for Project LUCY
8:15 – Atai Life Sciences To IPO soon on the Nasdaq and plans to raise $100 million
9:17 – Compass Pathways ( CMPS) to raise $144 million dollars
10:35 – Numinus Wellness ( NUMI ) to begin phase 1 trial for naturally extracted psilocybin in their lab
12:15 TRYP Therapeutics (TRYP) to begin 2 phase 2a trials in 2021
13:50 – Champignon Brands (SHRM) to restart trading in Canada
14:31 – Lobe Sciences (LOBE) & Core one Labs ( CLABF) to create a Joint Venture
15:34 – Red Light Holland (TRUFF) has increased its points of sale by 144% and TRUFF and Halo Collective create Red Light Oregn, INC

Link to Numinus (NUMI) press release: https://www.newswire.ca/news-releases/numinus-announces-phase-1-clinical-trial-of-natural-psilocybin-mushroom-extraction-prepared-at-company-lab-879795202.html?fbclid=IwAR1SmpbsTmXLs-mEy3vsUtAGKKk_xpf3FxJB3n2C-55zGJjiF0naXRetoUs

Link to Compass Pathways (CMPS) : https://www.globenewswire.com/news-release/2021/04/27/2218191/0/en/COMPASS-Pathways-launches-proposed-public-offering.html https://ir.compasspathways.com/static-files/fe6cc477-a2ee-4b4a-bd46-8f8df0b62f30

Link To Atai life Sciences: https://www.atai.life/

Link To MindMed (MMED / MNMD / MMQ) https://mindmed.co/
Link to MindMed clinical trial: https://clinicaltrials.gov/ct2/show/NCT03153579?term=lsd+anxiety&draw=2&rank=1

Link to Red LIght Holland (TRUFF) : https://www.newsfilecorp.com/release/81879/Red-Light-Holland-and-Halo-Collective-Create-Red-Light-Oregon-Inc.-Forwarding-Intentions-to-Enter-Oregon-Medicinal-Psychedelic-Market
https://www.cnbc.com/2021/04/21/atai-ipo-peter-thiel-backed-psychedelics-firm-to-raise-100-million.html

Link to Champignon Brands (SHRM) : https://www.prnewswire.com/news-releases/champignon-brands-announces-revocation-of-cease-trade-orders-301275526.html

Link to DMT study: https://www.sciencedirect.com/science/article/pii/S2666915321000251?fbclid=IwAR1-0HC9fxkL2Z47TEubMGsrqKInj61xLvBK4OW_C3FEQgv5VomoCSoNeQo

Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌

Instagram: @psychedelicinvestor
Email: thepsychedelicinvestor@gmail.com
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

#MindMed #PsychedelicStocks #numiStock